On January 1st a scientific article on the mechanisms and the effect of the company’s wound gel was published in Science Translational Medicine.
Swedish startup Xinnate has developed a wound gel in collaboration with a research group at the University of Lund. In animal studies the gel has been shown to work better than conventional treatments.
Based on natural mechanisms
Professor Artur Schmidtchen and his team have for a long time studied natural mechanisms and substances that are involved in normal wound healing, and based on this knowledge they have developed a gel that reduces the amount of harmful bacteria and also has an immuno-modulating effect and suppresses the inflammation that occurs in the wound. The gel uses the body’s natural defense to promote healing.
The published result now shows that, in in vivo models, the gel provides a faster and better wound healing, describes the company.
“The data shows that the gel is effective, both in preventing and in treating infections in wounds. This discovery may lead to new sustainable treatments for would healing. It may prevent infections, improve the healing process and decrease the dependence of antibiotics. In the same time it could decrease healthcare costs since many of today’s complications requires hospital care,” says Helene Hartman, CEO, Xinnate.
Patents and clinical studies
The company has now filed for patent for the gel and it is developed together with the researchers. Clinical studies are planned to begin during the second half of 2020.
Photo of the Board of Xinnate: Bo Benell, chairman, Helene Hartman, founder, Artur Schmidtchen, founder and Johan Jensen, financial advisory